Tirzepatide, a dual GIP/GLP-1 agonist, has shown even greater weight loss than semaglutide in clinical trials
GLP-1 medications address some of these limitations by modulating the reward value of food and slowing gastric emptying, which creates physical fullness independent of appetite suppression
The practical application: prioritize protein at every meal (25-40 grams), include at least 25-30 grams of daily fiber, and rotate through diverse plant foods to support microbiota diversity
Neither platform conducts in-person examinations or requires laboratory work before initial prescribing for most patients
After blocking, membranes were incubated with primary antibodies against SLC7a11 (1:1000, Abcam), GPX4 (1:1,000, Abcam), and PPAR (1:1,000